Nuclear medicine has come a long way since Henri Becquerel first observed the penetrating energy of radioactive materials in 1896. Today, technetium-99m alone is used in more than 40 million diagnostic procedures every year—from cardiovascular imaging and bone scans to cancer detection—making it the undisputed workhorse of nuclear medicine. That single statistic tells you something important: An enormous portion of modern diagnostic medicine rests on a surprisingly narrow foundation, one built around a small number of aging research reactors that were never originally designed for continuous isotope production.

Orano Group subsidiary Orano Med, a developer of targeted alpha therapies for oncology, inaugurated the expansion of its main research and development center located in Plano, Texas. The facility is used in the development of radiopharmaceuticals and for conducting preclinical research focused on targeted alpha therapies using lead-212, an alpha-emitting radioisotope that has shown promise in treating various types of cancer.